Ritter Pharmaceuticals, Inc
Ritter Pharmaceuticals, Inc.(NASDAQ: RTTR) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The company is further exploring and translating the functionality gut microbiome changes may have on improving gut health and its therapeutic potential to treat/prevent a variety of gastrointestinal diseases.
7-day free trial · no credit card
Verified contacts
6
available on Kipplo
LinkedIn employees
6
11 to 50 range
Open roles
—
no listings
Distinct roles
6
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 6 verified contacts at Ritter Pharmaceuticals, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
6 contacts with verified email or phone · masked until revealed.
- CB
Cindy Beckman
Independent Executive Office Professional · Other
EmailPhone - RT
Robert Tidwell
Chief Business Officer · General Business & Management
EmailPhone
Showing 2 of 6 verified contacts
Top roles at Ritter Pharmaceuticals, Inc
6 distinct titles indexed · top 6 shown.
- 1chief business officer
- 1formada
- 1gerente comercial regional
- 1independent executive office professional
- 1lactose intolerance product
- 1medical supervisor
Sign up to unlock all 6 contacts at Ritter Pharmaceuticals, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 6 verified contacts at Ritter Pharmaceuticals, Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.